Grigorios Siokas Buys 493,495 Shares of Cosmos Health (NASDAQ:COSM) Stock

January 16, 2026 by InsiderTrades.com

Key Points

CEO Grigorios Siokas purchased 493,495 shares on Jan. 14 at about $0.45, raising his holdings to 7,738,474 shares after multiple recent buys—a ~6.8% increase that signals strong insider accumulation.
Zacks initiated coverage with a $4.50 per‑share valuation and cited growth/AI initiatives, and institutional buyers (e.g., Citadel) have increased positions, providing bullish sentiment though Zacks was paid for the report.
Fundamentals remain weak: Cosmos Health reported a recent EPS miss, has negative earnings and margins, a small market cap (~$20M) and high beta, implying elevated near‑term earnings and volatility risk.

Cosmos Health Inc. (NASDAQ:COSM - Get Free Report) CEO Grigorios Siokas purchased 493,495 shares of the business's stock in a transaction dated Wednesday, January 14th. The shares were purchased at an average cost of $0.45 per share, with a total value of $222,072.75. Following the acquisition, the chief executive officer owned 7,738,474 shares in the company, valued at $3,482,313.30. This trade represents a 6.81% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.

Cosmos Holdings May be a Long-Term Buy with Short-Term Risk

Grigorios Siokas also recently made the following trade(s):

On Monday, January 12th, Grigorios Siokas acquired 113,185 shares of Cosmos Health stock. The stock was purchased at an average cost of $0.50 per share, for a total transaction of $56,592.50.
On Thursday, January 8th, Grigorios Siokas bought 156,190 shares of Cosmos Health stock. The stock was acquired at an average cost of $0.52 per share, for a total transaction of $81,218.80.
On Wednesday, January 7th, Grigorios Siokas purchased 124,880 shares of Cosmos Health stock. The shares were acquired at an average cost of $0.52 per share, with a total value of $64,937.60.
On Tuesday, January 6th, Grigorios Siokas acquired 133,953 shares of Cosmos Health stock. The shares were acquired at an average price of $0.54 per share, with a total value of $72,334.62.
On Friday, December 19th, Grigorios Siokas acquired 88,314 shares of Cosmos Health stock. The stock was acquired at an average cost of $0.49 per share, for a total transaction of $43,273.86.
On Monday, December 15th, Grigorios Siokas bought 168,472 shares of Cosmos Health stock. The stock was acquired at an average price of $0.42 per share, for a total transaction of $70,758.24.
On Friday, November 28th, Grigorios Siokas bought 76,360 shares of Cosmos Health stock. The stock was bought at an average cost of $0.64 per share, with a total value of $48,870.40.
On Tuesday, November 25th, Grigorios Siokas purchased 55,732 shares of Cosmos Health stock. The stock was bought at an average price of $0.63 per share, for a total transaction of $35,111.16.
On Friday, November 21st, Grigorios Siokas acquired 56,080 shares of Cosmos Health stock. The shares were bought at an average price of $0.68 per share, with a total value of $38,134.40.
On Thursday, November 20th, Grigorios Siokas acquired 51,315 shares of Cosmos Health stock. The stock was bought at an average cost of $0.62 per share, with a total value of $31,815.30.

Cosmos Health Stock Performance

Shares of Cosmos Health stock opened at $0.54 on Friday. The company's 50 day moving average price is $0.56 and its two-hundred day moving average price is $0.73. The firm has a market capitalization of $20.28 million, a P/E ratio of -0.72 and a beta of 5.37. Cosmos Health Inc. has a fifty-two week low of $0.28 and a fifty-two week high of $1.32. The company has a debt-to-equity ratio of 0.25, a current ratio of 0.99 and a quick ratio of 0.84.

Cosmos Health (NASDAQ:COSM - Get Free Report) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.16). The firm had revenue of $17.11 million during the quarter, compared to the consensus estimate of $16.40 million. Cosmos Health had a negative net margin of 31.01% and a negative return on equity of 33.19%. On average, equities analysts forecast that Cosmos Health Inc. will post -0.78 earnings per share for the current fiscal year.

Key Cosmos Health News

Here are the key news stories impacting Cosmos Health this week:

Positive Sentiment: Material CEO insider buying — CEO Grigorios Siokas disclosed a purchase of 493,495 shares at ~$0.45 on Jan. 14 (raising his stake by ~6.8%), adding to multiple buys earlier in January. Insider accumulation signals management confidence and likely helped lift the stock. Insider SEC Filing
Positive Sentiment: Zacks Small‑Cap Research initiated coverage with a $4.50 per‑share valuation, highlighting vertical integration, U.S. expansion (ZipDoctor, Sky Premium Life), AI R&D (Cloudscreen), and projected revenue growth to ~$130M+ by 2027 — a bullish research catalyst that likely boosted sentiment. Zacks Initiation
Positive Sentiment: Institutional interest — filings show several hedge funds/institutions (e.g., Citadel, Vanguard, Renaissance) added or increased positions in recent quarters, suggesting growing institutional attention that can support liquidity and price appreciation. Quiver Summary
Neutral Sentiment: Zacks’ forward estimates show an eventual path to positive EPS (FY2027 ~$0.07) but are model‑driven and rely on execution, R&D progress, and U.S. expansion. These are upside scenarios rather than confirmed results. Zacks Estimates
Negative Sentiment: Operating and profitability risks — recent quarterly results showed an EPS miss and negative margins/ROE; consensus still forecasts a full‑year loss (~‑$0.78), keeping near‑term earnings risk elevated. MarketBeat Financials
Negative Sentiment: Valuation caveats and disclosure — Zacks used a high (20%) discount rate and Cosmos paid Zacks for the report; model assumptions and the sponsor disclosure increase execution and impartiality risk. Zacks Disclosure
Negative Sentiment: High volatility and mixed sell‑side sentiment — small market cap, high beta and an average sell rating from brokers mean the stock can swing sharply; consider the higher risk profile before trading. MarketBeat Coverage

Institutional Inflows and Outflows

An institutional investor recently raised its position in Cosmos Health stock. Citadel Advisors LLC grew its position in Cosmos Health Inc. (NASDAQ:COSM - Free Report) by 133.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 225,507 shares of the company's stock after purchasing an additional 128,776 shares during the quarter. Citadel Advisors LLC owned approximately 0.65% of Cosmos Health worth $250,000 as of its most recent filing with the SEC. 12.61% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on COSM. Weiss Ratings restated a "sell (d-)" rating on shares of Cosmos Health in a research report on Wednesday, October 8th. Wall Street Zen upgraded Cosmos Health to a "hold" rating in a report on Saturday, September 20th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of "Sell".

Get Our Latest Stock Analysis on Cosmos Health

Cosmos Health Company Profile

(Get Free Report)

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.